Analysts Set Expectations for Ikena Oncology, Inc.’s Q1 2024 Earnings (NASDAQ:IKNA)

Ikena Oncology, Inc. (NASDAQ:IKNA – Get Rating) – Equities research analysts at William Blair issued their Q1 2024 earnings per share (EPS) estimates for shares of Ikena Oncology in a report issued on Tuesday, March 14th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of ($0.70) for the quarter. The consensus estimate for Ikena Oncology’s current full-year earnings is ($2.44) per share. William Blair also issued estimates for Ikena Oncology’s Q2 2024 earnings at ($0.75) EPS, Q3 2024 earnings at ($0.78) EPS, Q4 2024 earnings at ($0.82) EPS and FY2027 earnings at ($5.24) EPS.

A number of other research firms have also recently commented on IKNA. Credit Suisse Group lowered their target price on Ikena Oncology from $16.00 to $13.00 and set an “outperform” rating for the company in a research note on Wednesday. HC Wainwright lowered their price objective on Ikena Oncology from $26.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, November 29th.

Ikena Oncology Stock Up 1.2 %

IKNA opened at $4.30 on Thursday. The stock has a market cap of $155.92 million, a PE ratio of -2.97 and a beta of 0.80. The business has a 50 day moving average of $3.91 and a 200-day moving average of $3.40. Ikena Oncology has a 52 week low of $1.94 and a 52 week high of $8.99.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in IKNA. Millennium Management LLC purchased a new position in Ikena Oncology during the fourth quarter valued at $27,000. Virtu Financial LLC purchased a new position in shares of Ikena Oncology in the second quarter worth $69,000. Dimensional Fund Advisors LP raised its stake in shares of Ikena Oncology by 14.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 28,682 shares of the company’s stock worth $77,000 after purchasing an additional 3,537 shares during the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Ikena Oncology by 163.4% in the second quarter. Cubist Systematic Strategies LLC now owns 20,720 shares of the company’s stock worth $92,000 after purchasing an additional 12,854 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Ikena Oncology by 25.4% in the first quarter. JPMorgan Chase & Co. now owns 17,172 shares of the company’s stock worth $104,000 after purchasing an additional 3,482 shares during the last quarter. Hedge funds and other institutional investors own 72.40% of the company’s stock.

Ikena Oncology Company Profile

(Get Rating)

Ikena Oncology, Inc, a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.